ライフサイエンスコーパス: insulin receptor substrate

1 sozyme (RCAM-lysozyme), a well characterized insulin receptor substrate.

2 Both downregulation of insulin receptor substrate 1 (IRS-1) and dominant-negati

3 Insulin receptor substrate 1 (IRS-1) and IRS-2 are cytop

4 Furthermore, we showed that the insulin receptor substrate 1 (IRS-1) expression and insu

5 Furthermore, the expression of insulin receptor substrate 1 (IRS-1) phosphorylated at s

6 Insulin increased AKT and insulin receptor substrate 1 (IRS-1) phosphorylation, sy

7 Insulin receptor substrate 1 (IRS-1) plays a key role in

8 ation factor 4E (eIF4E) S209, Smad2 S465/67, insulin receptor substrate 1 (IRS-1) S612, mitogen-activ

9 egative feedback loop imposed on the IGF-IR- insulin receptor substrate 1 (IRS-1) signaling complex,

10 (SOCS3) show lower phosphorylation levels of insulin receptor substrate 1 (IRS-1) Tyr(896) and Akt Se

11 Similarly, the docking protein insulin receptor substrate 1 (IRS-1) was down-regulated

12 In this report, we identified insulin receptor substrate 1 (IRS-1), a critical mediato

13 th decreased levels of serine-phosphorylated insulin receptor substrate 1 (IRS-1), a molecule implica

14 ylation of JNK and serine phosphorylation of insulin receptor substrate 1 (IRS-1), along with inhibit

15 -1R, ALK fusion proteins bind to the adaptor insulin receptor substrate 1 (IRS-1), and IRS-1 knockdow

16 ling (SOCS3) in muscle, which led to loss of insulin receptor substrate 1 (IRS-1), thereby impairing

17 pogenesis, we examined the effect of BMP7 in insulin receptor substrate 1 (IRS-1)-deficient brown pre

18 in spite of decreased signaling through the insulin receptor substrate 1 (IRS-1)-phosphoinositide (P

19 n receptor substrates (IRS), one of which is insulin receptor substrate 1 (IRS-1).

20 et of rapamycin)-mediated phosphorylation of insulin receptor substrate 1 (IRS-1).

21 (IGF-I) signal through the scaffold protein insulin receptor substrate 1 (IRS-1).

22 e peptides (dilp2-3,5(-/-)) and mice lacking insulin receptor substrate 1 (Irs1(-/-)), and two indepe

23 KD cells reduced tyrosine phosphorylation of insulin receptor substrate 1 (IRS1) (pY(896)) and phosph

24 sistance because of enhanced skeletal muscle insulin receptor substrate 1 (IRS1) and Akt phosphorylat

25 These effects are mediated by insulin receptor substrate 1 (IRS1) and IRS2, which also

26 is critical for the membrane recruitment of insulin receptor substrate 1 (IRS1) and signal transmiss

27 nsulin resistance by increase in Ser(P)(307)-insulin receptor substrate 1 (IRS1) and subsequent decli

28 At 32 weeks, lower insulin receptor substrate 1 (IRS1) at S636/639 and Akt

29 ase, leading to increased phosphorylation of insulin receptor substrate 1 (IRS1) at serine 307.

30 based gene expression profiling we found the insulin receptor substrate 1 (IRS1) gene as one of the m

31 Common genetic variants in the insulin receptor substrate 1 (IRS1) gene have been recen

32 lele of rs2943641 near the gene encoding for insulin receptor substrate 1 (IRS1) has been associated

33 Mechanistically, insulin receptor substrate 1 (Irs1) is a direct target o

34 Insulin receptor substrate 1 (IRS1) is a key mediator of

35 e reverse-phase protein array, we found that insulin receptor substrate 1 (IRS1) is the most highly u

36 ion against insulin resistance by increasing insulin receptor substrate 1 (IRS1) levels.

37 kinase A (PKA)-dependent phosphorylation of insulin receptor substrate 1 (IRS1) on tyrosine residues

38 known node of PI3K inhibition and decreased insulin receptor substrate 1 (IRS1) protein levels.

39 SHH-treated CGNPs showed increased levels of insulin receptor substrate 1 (IRS1) protein, which was a

40 that has been shown to specifically degrade insulin receptor substrate 1 (IRS1) protein.

41 dent receptor autophosphorylation as well as insulin receptor substrate 1 (IRS1) tyrosine phosphoryla

42 Insulin receptor substrate 1 (IRS1) was overexpressed in

43 ndent proteolysis of the CRL7 target protein insulin receptor substrate 1 (IRS1), a component of the

44 insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS1), activation of prote

45 o trigger multisite seryl phosphorylation of insulin receptor substrate 1 (IRS1), leading to its ubiq

46 LKB1 deletion markedly reduced the levels of insulin receptor substrate 1 (IRS1), peroxisome prolifer

47 PI3K; thus, we examined the requirement for insulin receptor substrate 1 (IRS1), which binds and act

48 h "feedback" phosphorylation of the upstream insulin receptor substrate 1 (IRS1).

49 MiR-487b is predicted to target insulin receptor substrate 1 (IRS1).

50 involves ubiquitin-dependent degradation of insulin receptor substrate 1 (IRS1).

51 of HNF-4A gene (rs2144908 and rs1884614) and insulin receptor substrate 1 (rs1801278) are significant

52 the level of the insulin receptor, increased insulin receptor substrate 1 (Ser-312), and decreased Ak

53 884614, OR=2.44, CI=1.42-4.48, P=0.002), and insulin receptor substrate 1 AA+AG (rs1801278, OR=2.71,

54 a mouse model that harbors hepatic-specific insulin receptor substrate 1 and 2 deletions (double kno

55 port a non-canonical interaction between the insulin receptor substrate 1 and certain oncogenic varia

56 e, with dramatically decreased expression of insulin receptor substrate 1 and glucose transporter 4 i

57 tenuates insulin signaling and expression of insulin receptor substrate 1 and phosphoinositide 3-kina

58 because of the impaired interaction between insulin receptor substrate 1 and the p85alpha subunit of

59 ed protein kinase (AMPK), and phosphorylated insulin receptor substrate 1 at serine 307 (IRS1-s307).

60 The insulin-like growth factor I/insulin receptor substrate 1 axis controls, in a nonredu

61 found greater inhibitory phosphorylation of insulin receptor substrate 1 in each brain region examin

62 y 29% +/- 13% and phosphorylation of Akt and insulin receptor substrate 1 increased by 35% +/- 9% and

63 eficient in cyclin D2 (D2KO) with either the insulin receptor substrate 1 knockout (IRS1KO) mice or t

64 sses forkhead box O3, B-cell lymphoma 2, and insulin receptor substrate 1 mRNAs in the cocultured SMC

65 vity and reduced glucocorticoid induction of insulin receptor substrate 1 phosphorylation at serine 3

66 duced Jun NH2-terminal kinase activation and insulin receptor substrate 1 serine phosphorylation in v

67 inase activity by 183 +/- 6% (p = 0.003) and insulin receptor substrate 1 tyrosine phosphorylation by

68 s reduced, whereas serine phosphorylation of insulin receptor substrate 1 was elevated.

69 ith these changes, serine phosphorylation of insulin receptor substrate 1 was reduced, and Akt activa

70 scle expression of insulin receptor beta and insulin receptor substrate 1 were down-regulated 2-fold

71 s to stimulate YXXM phosphorylation of IRS1 (insulin receptor substrate 1) required for PI3K/AKT acti

72 egulin, and glucose metabolism-involved gene insulin receptor substrate 1), and 27 genes in the nondi

73 sduction by impairing the phosphorylation of insulin receptor substrate 1, a protein that couples act

74 We showed that MEMO1 binds to insulin receptor substrate 1, activates the downstream P

75 es and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin

76 ta-catenin, c/EBPalpha,c-Myc, cyclin D1, and insulin receptor substrate 1, and cell growth/survival.

77 syl phosphorylation of the insulin receptor, insulin receptor substrate 1, and their downstream casca

78 phorylation of type I IGF receptor (IGF-IR), insulin receptor substrate 1, phosphatidylinositol 3-kin

79 rylation in muscle may explain the increased insulin receptor substrate 1, PI3K, and ERK phosphorylat

80 stabilization of a second messenger protein, insulin receptor substrate 1, that mediates PI 3-kinase-

81 s associated with reduced insulin-stimulated insulin receptor substrate 1- (IRS-1-) and IRS-2-associa

82 stance through inhibitory phosphorylation of insulin receptor substrate 1.

83 e a requirement of Rab5 in presenting p85 to insulin receptor substrate 1.

84 r and Akt as well as decreased expression of insulin receptor substrate 1.

85 that PKC activation differentially inhibited insulin receptor substrate 1/2 (IRS1/2) signaling of ins

86 as evidenced by increased phosphorylation of insulin receptor substrate 1/2 and enhanced ERK/Akt acti

87 cing a negative feedback signal that targets insulin receptor substrates 1 and 2 (IRS1 and -2).

88 stance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are

89 Insulin receptor substrates 1 and 2 (IRS1/2) mediate mit

90 insulin signaling through phosphorylation of insulin-receptor substrates 1 and 2 at sites that interf

91 Insulin-stimulated phosphorylation of insulin receptor substrate-1 (IRS-1) and -2, and Akt was

92 owed that E2 influenced on protein levels of insulin receptor substrate-1 (IRS-1) and impaired insuli

93 ugh both proteasome-dependent degradation of insulin receptor substrate-1 (IRS-1) and inhibition of t

94 owing to the deletion of the genes encoding insulin receptor substrate-1 (Irs-1) and Irs-2 (referred

95 IGF-1 stimulates tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-2 and their

96 Insulin receptor substrate-1 (IRS-1) and IRS-2 are known

97 igands for ALK and that upon ALK activation, insulin receptor substrate-1 (IRS-1) and other substrate

98 ylation of c-Jun N-terminal kinase (JNK) and insulin receptor substrate-1 (IRS-1) at Ser-307 were inc

99 I) 3-kinase/Akt signaling by phosphorylating insulin receptor substrate-1 (IRS-1) at Ser-636/639.

100 Serine phosphorylation of insulin receptor substrate-1 (IRS-1) can regulate tyrosi

101 ke growth factor receptor (IGF-IR) or of the insulin receptor substrate-1 (IRS-1) genes in animals ca

102 activity of PI3K/protein kinase B (AKT) and insulin receptor substrate-1 (IRS-1) in the hypothalamic

103 The insulin receptor substrate-1 (IRS-1) is a docking protei

104 Insulin receptor substrate-1 (IRS-1) is a signaling adap

105 ses a route that promotes phosphorylation of insulin receptor substrate-1 (IRS-1) on Tyr(989), a cano

106 EFs and several other cell lines requires an insulin receptor substrate-1 (IRS-1) phosphorylated on t

107 Insulin receptor substrate-1 (IRS-1) plays a central rol

108 Our studies revealed that insulin receptor substrate-1 (IRS-1) protein levels decr

109 showed that IGF-I, IGF-IR mRNAs, and phospho-insulin receptor substrate-1 (IRS-1) protein were decrea

110 decreased insulin signaling at the level of insulin receptor substrate-1 (IRS-1) tyrosine phosphoryl

111 In fact, Ad-36 decreased insulin receptor substrate-1 (IRS-1) tyrosine phosphoryl

112 of IGF-I-induced cell cycle progression and insulin receptor substrate-1 (IRS-1) tyrosine phosphoryl

113 These effects are mediated by insulin receptor substrate-1 (IRS-1) via the mitogen-act

114 phoinositide-3 kinase (PI3K) associated with insulin receptor substrate-1 (IRS-1) was attenuated (P <

115 The insulin receptor substrate-1 (IRS-1), a docking protein

116 a-catenin binds to and co-localizes with the insulin receptor substrate-1 (IRS-1), a docking protein

117 During insulin or NGF stimulation TrkA, insulin receptor substrate-1 (IRS-1), INSR (and presumab

118 tyrosine phosphorylation of the receptor and insulin receptor substrate-1 (IRS-1), leading to activat

119 ith cardiac hypertrophy and stress including insulin receptor substrate-1 (IRS-1), phosphatidyl inosi

120 The signaling protein insulin receptor substrate-1 (IRS-1), shown here to be a

121 -high cells, and this enhanced expression of insulin receptor substrate-1 (IRS-1), the principle intr

122 BT-20 cells do not express insulin receptor substrate-1 (IRS-1), which is known to

123 rtment within tumor cells, where it degraded insulin receptor substrate-1 (IRS-1).

124 ation and degradation of the adaptor protein insulin receptor substrate-1 (IRS-1).

125 ns increases Ser(312) phosphorylation of the insulin receptor substrate-1 (IRS-1).

126 ieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).

127 olling ROCK-dependent phosphorylation of the insulin receptor substrate-1 (IRS-1).

128 o regulate insulin signaling at the level of insulin receptor substrate-1 (IRS-1).

129 f key insulin signalling proteins, including insulin receptor substrate-1 (IRS-1).

130 ced phosphorylation of insulin receptor (IR)/insulin receptor substrate-1 (IRS-1)/Akt pathway in the

131 Activation of the insulin (IN)/insulin receptor substrate-1 (IRS-1)/mitogen-associated

132 within the phosphotyrosine-binding domain of insulin receptor substrate-1 (IRS-PTB), we have used NMR

133 -growth factor-1 signaling pathways, such as insulin receptor substrate-1 (IRS1) and IRS2, differenti

134 ide explained by attenuation of an mTORC1-to-insulin receptor substrate-1 (IRS1) feedback and reduced

135 The gene encoding insulin receptor substrate-1 (IRS1) represents a strong

136 Female mice haploinsufficient for insulin receptor substrate-1 (IRS1-het) are hyperinsulin

137 n turn affects serine 612 phosphorylation of insulin receptor substrate-1 (p612 IRS-1).

138 fADN decreased phosphorylation of insulin receptor substrate-1 (Tyr-608), Akt (Thr-308 and

139 and phosphoinositide 3-kinase decreased, and insulin receptor substrate-1 307 phosphorylation increas

140 timulate glucose transport and phosphorylate Insulin receptor substrate-1 and Akt.

141 Absence of LAR enhanced phosphorylation of insulin receptor substrate-1 and insulin receptor substr

142 In adipose, endotoxemia suppressed insulin receptor substrate-1 and markedly induced suppre

143 ling and known feedback mechanisms affecting insulin receptor substrate-1 and phosphatidylinositol 3-

144 TNF-alpha-mediated serine phosphorylation of insulin receptor substrate-1 and protein tyrosine phosph

145 it with the IGF-I receptor (IGF-IR) effector insulin receptor substrate-1 and with ErbB3, implicating

146 This identifies insulin receptor substrate-1 as a novel nonreceptor targ

147 insulin-mediated tyrosine phosphorylation of insulin receptor substrate-1 as well as Akt phosphorylat

148 We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates fe

149 effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedb

150 sen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, inhibited corne

151 2 interacts with and directly phosphorylates insulin receptor substrate-1 in cardiomyocytes, causing

152 phosphorylation of the insulin receptor and insulin receptor substrate-1 in response to insulin incr

153 , glycogen synthase, and protein kinase B or insulin receptor substrate-1 level was unchanged.

154 o insulin action, and 3) basal inhibition of insulin receptor substrate-1 may decrease insulin action

155 (8.4-fold, P < 0.01), paralleled by reduced insulin receptor substrate-1 mRNA expression (-0.7-fold,

156 d expression of the key downstream messenger insulin receptor substrate-1 phosphorylated at serine re

157 mRNA of the DUSP-5 and 2) increases hepatic insulin receptor substrate-1 phosphorylation at serine 6

158 We also found increased insulin receptor substrate-1 Ser(636) phosphorylation in

159 significant increases in glucose metabolism, insulin receptor substrate-1, and Akt activity in muscle

160 Skeletal muscle insulin receptor, insulin receptor substrate-1, and Akt contents were unch

161 insulin-signaling pathway (insulin receptor, insulin receptor substrate-1, and Akt).

162 and down-regulation of the insulin receptor, insulin receptor substrate-1, and GLUT4.

163 nase, enhances the serine phosphorylation of insulin receptor substrate-1, and increases the expressi

164 insulin signaling cascade (insulin receptor, insulin receptor substrate-1, p85, phosphatidylinositol

165 on of a positive feedback from mTORC1 to the insulin receptor substrate-1, which explains reduced sen

166 rylation of insulin receptor substrate-1 and insulin receptor substrate-1-associated phosphoinositide

167 Akt, FoxO1, and c-Src, but did not activate insulin receptor substrate-1-like insulin.

168 TNF-alpha-mediated serine phosphorylation of insulin receptor substrate-1.

169 prevailing model of S6K1 phosphorylation of insulin receptor substrate-1.

170 including sites on the insulin receptor and insulin receptor substrate-1.

171 f the mTOR complex 1-dependent regulation of insulin receptor substrate-1.

172 -induced phosphorylation of Akt, ERK1/2, and insulin receptor substrate-1/2 was decreased and followe

173 ermined the kinetics of dephosphorylation of insulin receptor substrate-1/2, Akt, and ERK1/2, phospho

174 ays: one mediated by STAT6, and the other by insulin receptor substrates-1 and -2 via activation of P

175 cking either insulin receptors (betaIRKO) or insulin receptor substrate 2 (betaIRS2KO).

176 Appropriate regulation of insulin receptor substrate 2 (IRS-2) expression in pancr

177 Insulin receptor substrate 2 (IRS-2) plays a critical ro

178 ubsequent 52% decrease in insulin-stimulated insulin receptor substrate 2 (IRS-2) tyrosine phosphoryl

179 that promotes beta-cell growth and survival, insulin receptor substrate 2 (IRS-2), is a member of a f

180 insulin-induced tyrosine phosphorylation of insulin receptor substrate 2 (IRS-2), whereas it had min

181 teins involved in insulin signaling, such as insulin receptor substrate 2 (IRS2) and glucose transpor

182 3-CDK4 complex, which in turn phosphorylates insulin receptor substrate 2 (IRS2) at serine 388, there

183 component of all types of diabetes, and the insulin receptor substrate 2 (IRS2) branch of signaling

184 The insulin receptor substrate 2 (Irs2) branch of the insuli

185 a/cAMP mediates these actions by stimulating insulin receptor substrate 2 (IRS2) expression.

186 s, proliferation, and survival by increasing insulin receptor substrate 2 (IRS2) levels and identify

187 Insulin receptor substrate 2 (IRS2) suppression induced

188 s is sufficient to enhance the expression of insulin receptor substrate 2 (IRS2) to levels observed i

189 2)-associated binding proteins 1-3 (GAB1-3), insulin receptor substrate 2 (IRS2), docking protein 1 (

190 mice lacking insulin signaling intermediate insulin receptor substrate 2 (IRS2), we confirmed that h

191 The study also provides strong evidence that insulin receptor substrate 2 (Irs2), which is known to h

192 ronic morphine-induced downregulation of the insulin receptor substrate 2 (IRS2)-thymoma viral proto-

193 Moreover, miR-33a and -b also target the insulin receptor substrate 2, an essential component of

194 results in enhanced IR signaling through the insulin receptor substrate 2-AKT pathway in beta-cells a

195 Insulin receptor substrate-2 (IRS-2) belongs to the IRS

196 related with tyrosine phosphorylation of the insulin receptor substrate-2 (IRS-2) in macrophages.

197 Insulin receptor substrate-2 (IRS-2) plays a critical ro

198 Insulin receptor substrate-2 (IRS-2) plays an essential

199 to abused drugs decreases the expression of insulin receptor substrate-2 (IRS-2; a protein involved

200 of sarcomas and found a marked induction of insulin receptor substrate-2 (IRS2) and phosphorylated A

201 hat mice heterozygous for a null mutation in insulin receptor substrate-2 (Irs2) display a 17% increa

202 3K signaling leads to feedback inhibition of insulin receptor substrate-2 (IRS2) expression, an upstr

203 Insulin receptor substrate-2 (Irs2) is a critical mediat

204 Here, we show that, in mice, less insulin receptor substrate-2 (Irs2) signaling throughout

205 We identify insulin receptor substrate-2 (Irs2), a known cAMP-respon

206 ing through direct and indirect induction of insulin receptor substrate-2 (Irs2), an essential insuli

207 ysis occurs normally in B cells deficient in insulin receptor substrate-2 or the p85alpha subunit of

208 The hepatic mRNA level of the HIF-2 target insulin receptor substrate-2 was higher, whereas that of

209 lts in decreased tyrosine phosphorylation of insulin receptor substrate-2 with impeded insulin signal

210 n key insulin-signaling molecules, including insulin receptor substrate-2, and substrate metabolism t

211 ic screen of HD, we found that activation of insulin receptor substrate-2, which mediates the signali

212 ximately 40% reduction in insulin-stimulated insulin receptor substrate-2-associated phosphatidylinos

213 Using mass spectrometric analysis insulin receptor substrate 4 (IRS-4) has been identified

214 One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IR

215 hyperinsulinemic-euglycemic clamp and muscle insulin receptor substrate and Akt phosphorylation demon

216 thways governing glucose metabolism, such as insulin receptor substrate and Akt substrate.

217 PKR also directly targets and modifies insulin receptor substrate and hence integrates nutrient

218 ased brain glucose uptake, activation of the insulin receptor substrate and of the PI3K/Akt signaling

219 phosphorylation nor the interaction between insulin receptor substrate and phosphatidylinositide 3-k

220 TNF-alpha inhibits the function of insulin receptor substrates and decreases the expression

221 teosomal degradation of the docking protein, insulin receptor substrate, and enhanced signaling throu

222 ugh serine phosphorylation and inhibition of insulin receptor substrate by the downstream effector of

223 Insulin receptor substrates, including Irs1 and Irs2, in

224 n the level of serine phosphorylation of the insulin receptor substrate IRS-1.

225 These foci contain the insulin receptor substrate (IRS) 1 adaptor molecule, and

226 easured the life span of mice lacking either insulin receptor substrate (IRS) 1 or 2, the major intra

227 Insulin receptor substrate (IRS) 2 as intermediate docki

228 IS/TOR network, including the critical nodes insulin receptor substrate (IRS) and phosphatidylinosito

229 The insulin receptor substrate (IRS) proteins are cytoplasmi

230 The insulin receptor substrate (IRS) proteins are cytoplasmi

231 ammatory cytokines induce phosphorylation of insulin receptor substrate (IRS) proteins at Ser sites t

232 The insulin receptor substrate (IRS) proteins represent a cr

233 The insulin receptor substrate (IRS) proteins serve as essen

234 ciated with reduced expression of both major insulin receptor substrate (IRS) proteins, IRS-1 and IRS

235 naling and the extent to which alteration of insulin receptor substrate (IRS) signaling modulates bet

236 The mRNA transcript levels of AAH, insulin receptor substrate (IRS), insulin and insulin-li

237 Mice with deletion of insulin receptor substrate (IRS)-1 (IRS-1 knockout [KO]

238 CS)3 deficiency increases insulin-stimulated insulin receptor substrate (IRS)-1 and -2 phosphorylatio

239 ficiency suppressed the up-regulation of the insulin receptor substrate (IRS)-1 and IRS-2 and thereby

240 Hepatic insulin receptor substrate (IRS)-1 and IRS-2 expression

241 l line decreased tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 in response

242 o delayed and impaired activation of hepatic insulin receptor substrate (IRS)-1 and IRS-2 signaling,

243 xpression of major IGF signaling components, insulin receptor substrate (IRS)-1 and IRS-2, an effect

244 of mRNAs for insulin receptor (IR)A and IRB; insulin receptor substrate (IRS)-1 and IRS-2; phosphoino

245 g SOCS3 and via SOCS3-mediated inhibition of insulin receptor substrate (IRS)-1 and possibly AMPK in

246 Suppression of insulin receptor substrate (IRS)-1 and tuberous sclerosi

247 Research has focused on insulin receptor substrate (IRS)-1 as a locus for insuli

248 association between genetic variants of the insulin receptor substrate (IRS)-1 gene, platelet functi

249 xamine the role of serine phosphorylation of insulin receptor substrate (IRS)-1 in mediating fat-indu

250 Ad-GLP-1 treatment increased basal levels of insulin receptor substrate (IRS)-1 in the liver and acti

251 in (10(-8) to 10(-7) m) for 0-24 h increased insulin receptor substrate (IRS)-1 phosphorylation at Se

252 yotubes, dexamethasone (> or = 24 h) reduced insulin receptor substrate (IRS)-1 protein and PI3K/Akt

253 ure to NO donor or iNOS transfection reduced insulin receptor substrate (IRS)-1 protein expression wi

254 tein kinase (PKC)theta activation, increased insulin receptor substrate (IRS)-1 serine 1101 phosphory

255 Insulin receptor and insulin receptor substrate (IRS)-1 serine hyperphosphory

256 rough inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signal

257 increased insulin receptor signaling, i.e., insulin receptor substrate (IRS)-1, insulin receptor pho

258 raised insulin-like growth factor-1 (IGF-1), insulin receptor substrate (IRS)-1, vascular endothelial

259 is, p85alpha mRNA and protein expression and insulin receptor substrate (IRS)-1-associated PI 3-kinas

260 Phosphorylation of insulin receptor substrate (IRS)-1/2 by IGF-I receptor t

261 betes reduced basal insulin receptor kinase, insulin receptor substrate (IRS)-1/2-associated phosphat

262 sulin-like growth factor receptor-1 (IGF-1R)/insulin receptor substrate (IRS)-1/Akt pathway with ERal

263 the insulin receptor catalytic activity and insulin receptor substrate (IRS)-1/IRS-2 dephosphorylati

264 educed strength of insulin signaling via the insulin receptor substrate (IRS)-1/phosphatidylinositol

265 -restricted phosphopeptides derived from the insulin receptor substrate (IRS)-2 and the cell-cycle re

266 bited insulin-induced Tyr phosphorylation of insulin receptor substrate (IRS)-2 protein and the activ

267 Furthermore, we also showed that insulin receptor substrate (IRS)-2, but not IRS-1, is in

268 13 bind IL-4 receptors, which signal through insulin receptor substrate (IRS)-2, inducing M2 macropha

269 ic glucose production and insulin-stimulated insulin receptor substrate (IRS)-2-associated phosphatid

270 Postreceptor signaling through the insulin receptor substrate (IRS)/PI3-K/Akt pathway was e

271 ikely caused by, direct dephosphorylation of insulin receptor substrate (IRS)1/2 in the liver, accomp

272 We found insulin receptor substrate (IRS)2 and enhanced-activated

273 Pituitaries responded to insulin through insulin receptor substrate (IRS)2 but not IRS1, whereas

274 ort an altered interrelationship between the insulin receptor substrate (IRS-1) and Akt/mTOR pathway

275 ociation with more phospho (P)-serine-type 1 insulin receptor substrate (IRS-1) and less P-tyrosine-I

276 When phosphorylated by mTORC1/S6K, the insulin receptor substrate (IRS-1) is targeted for ubiqu

277 ceptors (IR) resulting in phosphorylation of insulin receptor substrates (IRS) inducing activation of

278 e effects are mediated, at least in part, by insulin receptor substrates (IRS), one of which is insul

279 Insulin receptor substrates (Irs-proteins) integrate sig

280 ut displayed severely blunted signalling via insulin-receptor substrate (IRS) proteins, key mediators

281 d phosphorylation of IGF signaling molecules insulin-receptor substrate (IRS)-1 and IRS-2.

282 ne kinase (MCK)-Cre to disrupt expression of insulin receptor substrates Irs1 and Irs2 in mouse skele

283 resistin increased serine phosphorylation of insulin receptor substrate (IRS1) through the activation

284 tyrosine phosphorylation of adapter protein insulin receptor substrate (IRS1).

285 This is the result of downregulation of the insulin receptor substrates, IRS1 and IRS2, which become

286 Insulin receptor substrates (IRSs) are signaling adaptor

287 gnaling for energy uptake and growth through insulin receptor substrates (IRSs), which interact with

288 ion levels in the brain for two transcripts, insulin receptor substrate p53 (IRSp53) and Calsenilin.

289 ovel PDZ1 binding partner, the I-BAR protein insulin receptor substrate p53 (IRSp53).

290 improved insulin signal transduction via the insulin receptor substrate-phosphatidylinositol-3-hydrox

291 hese hormones induces cell signaling via the insulin receptor substrate/phosphatidylinositol 3-kinase

292 pathways in rodent beta-cells, including the insulin receptor substrate/phosphatidylinositol-3 kinase

293 ing selectively in endothelial cells via the insulin receptor substrate/PI3K/Akt pathway to reduce th

294 The 53 kDa insulin receptor substrate protein (IRSp53) is highly en

295 ess at least two Tiam1-interacting proteins, insulin receptor substrate protein 53 kDa (IRSp53) and s

296 DOK1 is a member of insulin receptor substrate protein family that binds bet

297 of the insulin signaling pathways engaged by insulin receptor substrate proteins.

298 ting Tyr-325 was not required for the robust insulin receptor substrate response.

299 results from differential downregulation of insulin receptor substrates that control phosphatidylino

300 sed muscle insulin signaling (phosphorylated insulin receptor substrate(Tyr) and Akt(Ser473) levels)